Research programme: aptamer-dicer substrate RNAi therapeutics - Archemix/DicernaAlternative Names: Aptamer-DsiRNA
Latest Information Update: 16 Nov 2012
At a glance
- Originator Archemix Corporation; Dicerna Pharmaceuticals
- Class Oligonucleotides; RNA
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 16 Nov 2012 Discontinued for Undefined indication in USA (Parenteral)
- 21 Jul 2009 Early research in Undefined indication in USA (Parenteral)